Cyclopharm Ltd (CYC) - Net Assets
Based on the latest financial reports, Cyclopharm Ltd (CYC) has net assets worth AU$31.86 Million AUD (≈ $22.55 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$49.68 Million ≈ $35.15 Million USD) and total liabilities (AU$17.81 Million ≈ $12.60 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Cyclopharm Ltd strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$31.86 Million |
| % of Total Assets | 64.14% |
| Annual Growth Rate | 4.45% |
| 5-Year Change | -37.05% |
| 10-Year Change | 117.55% |
| Growth Volatility | 58.97 |
Cyclopharm Ltd - Net Assets Trend (2005–2025)
This chart illustrates how Cyclopharm Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Cyclopharm Ltd worth.
Annual Net Assets for Cyclopharm Ltd (2005–2025)
The table below shows the annual net assets of Cyclopharm Ltd from 2005 to 2025. Also explore how fast is Cyclopharm Ltd growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | AU$27.11 Million ≈ $19.18 Million |
-36.55% |
| 2024-12-31 | AU$42.73 Million ≈ $30.23 Million |
+32.46% |
| 2023-12-31 | AU$32.26 Million ≈ $22.83 Million |
-11.71% |
| 2022-12-31 | AU$36.54 Million ≈ $25.85 Million |
-15.16% |
| 2021-12-31 | AU$43.07 Million ≈ $30.47 Million |
+151.62% |
| 2020-12-31 | AU$17.12 Million ≈ $12.11 Million |
-26.24% |
| 2019-12-31 | AU$23.20 Million ≈ $16.42 Million |
+36.37% |
| 2018-12-31 | AU$17.02 Million ≈ $12.04 Million |
-1.35% |
| 2017-12-31 | AU$17.25 Million ≈ $12.21 Million |
+38.42% |
| 2016-12-31 | AU$12.46 Million ≈ $8.82 Million |
-4.89% |
| 2015-12-31 | AU$13.10 Million ≈ $9.27 Million |
+68.93% |
| 2014-12-31 | AU$7.76 Million ≈ $5.49 Million |
+111.81% |
| 2013-12-31 | AU$3.66 Million ≈ $2.59 Million |
-76.54% |
| 2012-12-31 | AU$15.61 Million ≈ $11.04 Million |
+6.87% |
| 2011-12-31 | AU$14.60 Million ≈ $10.33 Million |
+6.09% |
| 2010-12-31 | AU$13.77 Million ≈ $9.74 Million |
-1.17% |
| 2009-12-31 | AU$13.93 Million ≈ $9.86 Million |
+6.69% |
| 2008-12-31 | AU$13.06 Million ≈ $9.24 Million |
+77.82% |
| 2007-12-31 | AU$7.34 Million ≈ $5.20 Million |
+1397.06% |
| 2006-12-31 | AU$-566.06K ≈ $-400.52K |
-104.99% |
| 2005-12-31 | AU$11.34 Million ≈ $8.02 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Cyclopharm Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6220402500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$87.07 Million | 321.17% |
| Other Comprehensive Income | AU$5.11 Million | 18.86% |
| Total Equity | AU$27.11 Million | 100.00% |
Cyclopharm Ltd Competitors by Market Cap
The table below lists competitors of Cyclopharm Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cengild Medical Berhad
KLSE:0243
|
$41.82 Million |
|
Haesung Optics Co. Ltd
KQ:076610
|
$41.85 Million |
|
EDM Resources Inc
V:EDM
|
$41.87 Million |
|
Mccoy Global Inc
TO:MCB
|
$41.88 Million |
|
Dae Hyun
KO:016090
|
$41.80 Million |
|
YNH Property Bhd
KLSE:3158
|
$41.80 Million |
|
TWL Holdings Bhd
KLSE:7079
|
$41.79 Million |
|
Reading International Inc
NASDAQ:RDI
|
$41.78 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cyclopharm Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 42,729,869 to 27,111,058, a change of -15,618,811 (-36.6%).
- Net loss of 17,219,906 reduced equity.
- Other comprehensive income increased equity by 1,601,095.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-17.22 Million | -63.52% |
| Other Comprehensive Income | AU$1.60 Million | +5.91% |
| Total Change | AU$- | -36.55% |
Book Value vs Market Value Analysis
This analysis compares Cyclopharm Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.91x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | AU$-0.02 | AU$0.47 | x |
| 2007-12-31 | AU$0.25 | AU$0.47 | x |
| 2008-12-31 | AU$0.43 | AU$0.47 | x |
| 2009-12-31 | AU$0.38 | AU$0.47 | x |
| 2010-12-31 | AU$0.37 | AU$0.47 | x |
| 2011-12-31 | AU$0.41 | AU$0.47 | x |
| 2012-12-31 | AU$0.34 | AU$0.47 | x |
| 2013-12-31 | AU$0.06 | AU$0.47 | x |
| 2014-12-31 | AU$0.13 | AU$0.47 | x |
| 2015-12-31 | AU$0.23 | AU$0.47 | x |
| 2016-12-31 | AU$0.22 | AU$0.47 | x |
| 2017-12-31 | AU$0.25 | AU$0.47 | x |
| 2018-12-31 | AU$0.25 | AU$0.47 | x |
| 2019-12-31 | AU$0.34 | AU$0.47 | x |
| 2020-12-31 | AU$0.22 | AU$0.47 | x |
| 2021-12-31 | AU$0.48 | AU$0.47 | x |
| 2022-12-31 | AU$0.40 | AU$0.47 | x |
| 2023-12-31 | AU$0.35 | AU$0.47 | x |
| 2024-12-31 | AU$0.42 | AU$0.47 | x |
| 2025-12-31 | AU$0.25 | AU$0.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cyclopharm Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -63.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -53.27%
- • Asset Turnover: 0.70x
- • Equity Multiplier: 1.70x
- Recent ROE (-63.52%) is below the historical average (-3.49%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 13.95% | 17.34% | 0.43x | 1.85x | AU$448.03K |
| 2006 | 0.00% | 19.63% | 1.14x | 0.00x | AU$2.08 Million |
| 2007 | 15.41% | 10.17% | 1.01x | 1.50x | AU$397.02K |
| 2008 | 13.46% | 16.14% | 0.59x | 1.42x | AU$451.51K |
| 2009 | 14.68% | 15.59% | 0.67x | 1.41x | AU$651.63K |
| 2010 | 3.27% | 4.76% | 0.43x | 1.61x | AU$-926.51K |
| 2011 | -6.55% | -9.27% | 0.48x | 1.46x | AU$-2.42 Million |
| 2012 | -6.69% | -9.72% | 0.50x | 1.39x | AU$-2.60 Million |
| 2013 | -21.30% | -6.56% | 1.32x | 2.46x | AU$-1.15 Million |
| 2014 | 52.42% | 33.75% | 1.10x | 1.41x | AU$3.29 Million |
| 2015 | 36.58% | 38.09% | 0.76x | 1.26x | AU$3.48 Million |
| 2016 | 7.15% | 6.20% | 0.88x | 1.32x | AU$-354.81K |
| 2017 | -8.84% | -11.56% | 0.56x | 1.36x | AU$-3.25 Million |
| 2018 | -0.21% | -0.26% | 0.57x | 1.38x | AU$-1.74 Million |
| 2019 | -12.55% | -20.69% | 0.43x | 1.40x | AU$-5.23 Million |
| 2020 | -35.31% | -41.18% | 0.52x | 1.65x | AU$-7.76 Million |
| 2021 | -11.70% | -28.47% | 0.32x | 1.29x | AU$-9.35 Million |
| 2022 | -18.10% | -28.47% | 0.47x | 1.36x | AU$-10.27 Million |
| 2023 | -14.57% | -17.85% | 0.57x | 1.42x | AU$-7.93 Million |
| 2024 | -30.89% | -47.87% | 0.44x | 1.45x | AU$-17.47 Million |
| 2025 | -63.52% | -53.27% | 0.70x | 1.70x | AU$-19.93 Million |
Industry Comparison
This section compares Cyclopharm Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $40,109,748
- Average return on equity (ROE) among peers: -41.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cyclopharm Ltd (CYC) | AU$31.86 Million | 13.95% | 0.56x | $41.81 Million |
| 4DMEDICAL Ltd (4DX) | $3.78 Million | -104.20% | 0.44x | $1.75 Billion |
| Adherium Ltd (ADR) | $-4.76 Million | 0.00% | 0.00x | $3.18 Million |
| Aroa Biosurgery Ltd (ARX) | $1.81 Million | 0.00% | 6.66x | $130.04 Million |
| Atomo Diagnostics Ltd (AT1) | $10.08 Million | -67.90% | 0.13x | $11.49 Million |
| Avita Medical Inc (AVH) | $3.98 Million | -125.89% | 0.98x | $188.51 Million |
| Anteris Technologies Global Corp (AVR) | $13.64 Million | -10.42% | 0.08x | $809.31 Million |
| Control Bionics Ltd (CBL) | $6.09 Million | -15.97% | 0.04x | $23.82 Million |
| Cardiex Ltd (CDX) | $1.88 Million | -105.36% | 1.22x | $13.23 Million |
| Compumedics Ltd (CMP) | $9.21 Million | -30.70% | 1.16x | $33.22 Million |
| Cochlear Ltd (COH) | $355.39 Million | 41.04% | 1.46x | $6.20 Billion |
About Cyclopharm Ltd
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribu… Read more